
IRVINE, August 26, 2026, 18:49 – Lantronix shares climbed 12.5% in after-hours trade as the company reported its unmanned systems segment is on track to account for 15%–20% of total sales.
Market data: August 26, 2026, 18:49 EDT (00:49 CEST). Financials: quarter and year ended June 30, 2026.
The 12.5% after-hours jump more than offset the regular-session decline. The combined gain was $0.51, or 8.7%, from Tuesday's close.
| Signal | FY26 actual | FY27 target / context |
|---|---|---|
| Revenue | $12.6M | 15%–20% of total revenue |
| Share of company sales | 10.4% | +4.6 to +9.6 points |
| Active engagements | >30 | About 10 at FY26 start |
| Equity value added | ≈$23.8M | 1.9× FY26 unmanned revenue |
The valuation calculation uses the $0.51 gain from the August 25 close and 46.59 million year-end shares.
| Metric | June 2026 | June 2025 | Change |
|---|---|---|---|
| Cash | $60.5M | $20.1M | +$40.4M |
| Debt | $0 | $11.8M | Eliminated |
| Shares outstanding | 46.59M | 39.10M | +19.2% |
| GAAP net loss | $4.2M | $11.4M | 63.2% narrower |
Published consensus before post-results revisions; checked August 26, 2026.
Long drone qualification cycles can delay revenue, while project timing makes quarterly orders uneven. Rising memory costs could compress margins. Acquisition integration and further share issuance would weaken per-share gains. The central invalidation signal is failure to convert more than 30 engagements into volume shipments while legacy systems revenue continues to fall.
Sources: Lantronix fiscal Q4/FY2026 release and earnings call; Yahoo Finance market data; MarketBeat analyst consensus. Non-GAAP measures exclude items defined by Lantronix and are not substitutes for GAAP results.
The rally created 6.6 times more quoted value than the board authorized for purchases.
*Combined Class A and B shares, Sept. 30, 2025 to Aug. 7, 2026.
| Measure | Latest | Prior/comparison | Investor signal |
|---|---|---|---|
| Cash + short-term investments | $362.6M | $251.9M at Sept. 30 | Large funding capacity, largely equity-raised |
| Six-month revenue | $2.57M | $2.42M | +6.1% year over year |
| Six-month RaaS revenue | $0.69M | $0.25M | +181.6%, but still small |
| Six-month operating cash flow | -$2.03M | -$4.94M | Burn improved |
| Combined shares outstanding | 225.10M | 194.59M | +15.7% since Sept. 30 |
| Implied shares at full buyback | 6.09M | At $1.97 | Only 19.9% of recent share increase |
| Company | Market cap | TTM revenue | Price / sales | Aug. 25 move |
|---|---|---|---|---|
| Richtech Robotics (RR) | $0.44B | $0.005B | 82.3× | +21.60% |
| Red Cat (RCAT) | $1.40B | $0.072B | 19.6× | +2.58% |
| Intuitive Surgical (ISRG) | $131.36B | $11.03B | 11.9× | -0.46% |
Peers illustrate scale and valuation dispersion, not direct operational comparability.
1 analyst · Hold
$2.00 target
1.5% above the $1.97 close; $1.99 after hours sat one cent below it.
Next proof points
Actual shares repurchased; new equity issuance; RaaS growth; operating cash use.
The program is discretionary and can be changed or stopped. A full purchase at Tuesday’s price would retire just 2.7% of shares. Further issuance could outweigh it. An 82× trailing-sales valuation increases sensitivity to execution and liquidity shifts.
Sources: Richtech Robotics Aug. 25 repurchase release; Richtech Robotics Form 10-Q for March 31, 2026; StockAnalysis market and financial pages; FinanceCharts volume history; Investing.com analyst poll. Calculations use 225.10 million shares and the Aug. 25 close.
The board authorized purchases of Class B stock through Aug. 21, 2027. No minimum purchase is required. The board may modify, pause or end the program without notice.
| Firm | Action | Rating | Target | Date | Vs. $1.89 |
|---|---|---|---|---|---|
| Freedom Broker | Upgrade | Hold | $2 | Aug. 16, 2026 | +5.8% |
| H.C. Wainwright | Reiterate | Buy | $6 | Feb. 2, 2026 | +217.5% |
Coverage is sparse. The target spread highlights unusually wide uncertainty around commercialization and valuation.
15.3% below the RMB26.61B LSEG consensus.
About 58% of XPeng's current equity value, but the deal does not fix the near-term earnings gap.
Nearly three times the prior-year loss and well above expectations.
Bank of America maintained Buy with a $19 target on August 24. The target range still sits above the share price, but forecasts may lag the new guidance.
China's EV price war can keep vehicle margins under pressure. Robotics investment may deepen losses before commercial sales begin. The Dogotix financing terms do not reveal XPeng's exact economic stake, so its $6.3 billion-plus valuation should not be treated as cash attributable to XPeng shareholders.
| Metric | Latest verified value |
|---|---|
| FY2025 adjusted net profit | ¥590.8m |
| FY2025 main-business gross margin | 60.13% |
| Overseas revenue share | 43.65% |
| Q1 2026 revenue growth | +68.49% |
| Q1 2026 adjusted profit growth | -52.55% |
| 2025 humanoid shipments | 5,500+ |
| Source | Published signal |
|---|---|
| CITIC, sponsor | ¥50.6bn–¥55.9bn pre-list value |
| Morningstar | Commercial ROI remains the test |
| Consensus | NOT AVAILABLE |
| Evidence to watch | Bull case | Bear case | Timing |
|---|---|---|---|
| Commercial deployments | Repeat industrial orders | Demo and research demand dominates | Next results |
| H1 2026 preliminary range | Revenue near ¥1.128bn | Adjusted profit near ¥236m | Interim filing |
| Margin path | Scale offsets price cuts | R&D and selling costs keep rising | Quarterly |
| Export mix | Europe offsets U.S. | Restrictions broaden | Ongoing |
Today’s highest-ranked model selections.